Diabirel

Quick links to important sections

Diabirel

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diabirel

Diabirel is a prescription-only medication primarily used to help adults with type 2 diabetes mellitus manage and maintain healthy blood sugar levels, utilized as an adjunct to diet and exercise regimens.

Property Description
Active ingredient Glimepiride
Form Oral Tablet
Pharmacological class Sulfonylurea, Insulin Secretagogue
Common use Glycemic Control in Type 2 Diabetes
Origin Synthetic Chemical Compound

What Type of Medicine is Diabirel (Glimepiride)?

Diabirel is classified as a sulfonylurea and an insulin secretagogue, distinguishing it as a second-generation compound within the broader Antidiabetic Agent class. The core active ingredient, Glimepiride, is a potent compound whose action relies on the patient having residual activity in the pancreatic beta-cells. Unlike certain other diabetes treatments, Glimepiride's main mechanism involves working on the pancreas to stimulate the natural release of the body's own insulin, which is why it is identified as a secretagogue. Glimepiride is clinically recognized for its consistent, once-daily effectiveness in lowering blood glucose levels.


Is Diabirel a Synthetic Compound? Composition and Form

Yes, the active ingredient in Diabirel, Glimepiride, is a synthetic chemical entity and a small molecule compound that is manufactured for consistent efficacy. Glimepiride is a synthetic compound chemically distinct from earlier sulfonylureas. Diabirel is an oral medication, typically presented for administration as a tablet that must be swallowed. As a monotherapy preparation, the tablets contain Glimepiride alongside solid pharmaceutical excipients necessary for the stable formulation of the medication. The drug is often used when a patient requires a primary boost to their natural insulin secretion, and it is frequently positioned for its use in patients requiring monotherapy to manage their condition.


What is the Main Purpose of Taking Diabirel?

By promoting the pancreatic release of insulin and enhancing the sensitivity of peripheral tissues to the insulin that is available, the main purpose of taking Diabirel is to lower and control high levels of blood glucose. Glimepiride's primary mechanism involves the closure of KATP channels on beta-cells, leading to enhanced insulin secretion. These combined physiological actions support the body’s ability to process and utilize sugar more effectively, making Diabirel a critical component in achieving and sustaining desired glycemic control over time.

What side effects are possible with Diabirel?

Possible Side Effects and Safety Information

The safety profile of Diabirel (Glimepiride) is officially categorized by governmental regulatory authorities based on the frequency and the organ system affected. This provides a structured overview of potential adverse effects consistent with official product information.

Frequency-Classified Adverse Reactions

The most frequently documented adverse reaction is hypoglycemia (low blood sugar), which is officially classified as a common event. Other effects are categorized based on their rate of occurrence:

  • Common: Hypoglycemia.
  • Uncommon: Gastrointestinal disturbances (such as nausea, vomiting, or diarrhea) and transient visual impairment.
  • Rare: Serious reactions including certain blood and lymphatic system disorders (such as agranulocytosis or aplastic anemia), hepatitis, and severe hypersensitivity reactions like allergic vasculitis.

Serious and Systemic Safety Considerations

Adverse effects are documented across several physiological systems. The official label notes the potential for serious adverse reactions, particularly those affecting the hematopoietic system and liver. Severe hypoglycemia and severe hepatic impairment are documented as serious safety concerns in official prescribing information.

Time-Related Patterns: Regulatory documentation notes that certain effects, including hypoglycemia and transient visual impairment, may be observed more frequently at the start of treatment or following a dose adjustment.

Population-Specific Notes: Safety considerations are specified for certain groups. For instance, there is a recognized increased susceptibility to hypoglycemia in older adults. Furthermore, the use of Glimepiride is officially contraindicated in individuals with severe hepatic impairment.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of a medicine like Diabirel, an oral anti-diabetic agent, occurs when more than the prescribed amount is taken, which can result in a profound and potentially life-threatening drop in blood sugar levels, known as hypoglycemia.

Documented Overdose Presentations

An overdose is characterized by severe hypoglycemia, which primarily affects the central nervous system (CNS) and cardiovascular system. Symptoms may include:

  • Early Signs: Sweating, nervousness, tremor, anxiety, confusion, rapid heartbeat.
  • Severe Signs: Stupor, coma (decreased level of consciousness), apathy, and convulsions or seizures (especially in children).

Risk factors for severe, prolonged hypoglycemia include advanced age, poor nutritional status, and pre-existing kidney or liver impairment. Ingestion of even a small amount can cause serious toxicity in non-diabetic adults and children.

Required Emergency Actions

Immediate medical attention is required for any suspected overdose. The official guidance emphasizes that you should call your local emergency number (such as 911) or the Poison Help hotline (1-800-222-1222) immediately for instructions. Take the medicine container to the hospital, if possible, where medical personnel will monitor vital signs and perform necessary tests (e.g., blood glucose levels, ECG).

Treatment often involves the prompt administration of intravenous fluids containing glucose, and potentially other medications to prevent recurrent hypoglycemia, as the effects of the overdose may be prolonged for 24 hours or more. Without timely correction, severe overdose carries the risk of permanent brain damage and death.

Therapeutic Uses of Diabirel

What Diabirel Treats: Main Uses and Benefits

Diabirel is a prescription medication generally used to manage Type 2 Diabetes Mellitus in adults. It is applied in clinical settings that involve symptoms related to systemic imbalance, when other forms of management are insufficient. The drug is applied in addressing the symptoms related to systemic imbalance and is commonly used to help manage chronic hyperglycemia, elevated fasting blood glucose levels, postprandial hyperglycemia, and high Glycated Hemoglobin (HbA1c) values.


The primary therapeutic focus is relevant for easing systemic imbalance, which may include sustained glycemic control in conditions characterized by periods of heightened symptoms. This supports the patient during difficult episodes and may contribute to a reduction in the risk of serious, long-term complications affecting the eyes, nerves, and cardiovascular system. The medication is relevant when supportive symptom management is appropriate, often used as an adjunct to diet and exercise regimens, or in monotherapy or combination therapy when a comprehensive treatment strategy is considered relevant.


Quick Fact: Relief for Chronic Hyperglycemia The medication may assist with maintaining functional stability when blood sugar levels are noticeably high.

Regulatory References

  1. NIH MedlinePlus overview of Glimepiride

Eligibility and Restrictions for Use

The eligibility for Diabirel (Glimepiride) is strictly limited to Adults with Type 2 Diabetes Mellitus (T2DM). Official regulatory documents define clear population groups who must not use the medicine (contraindications) and specific conditions that require restricted use.


Official Eligibility Status

Category Regulatory Status (Excerpt)
Populations for whom use is allowed Adults with Type 2 Diabetes Mellitus only.
Populations for whom use is contraindicated Type 1 Diabetes Mellitus, Diabetic Ketoacidosis (DKA), and known hypersensitivity to Glimepiride or Sulfonamide Derivatives.
Pregnancy and Lactation Contraindicated during pregnancy and not recommended during breastfeeding.
Age-related restrictions Pediatric use is not recommended; safety and effectiveness have not been established.
Condition-specific restrictions Severe renal or hepatic function disorders are contraindicated by some authorities, requiring a change to insulin. Use requires caution in older adults and patients with less severe renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Diabirel (Glimepiride) is structured around its metabolic pathway and the potential for pharmacodynamic changes in glycemic control. The drug’s metabolism is primarily dependent on the Cytochrome P450 2C9 (CYP2C9) enzyme. Regulatory documents explicitly describe interactions with CYP2C9 inhibitors, such as Fluconazole, which may increase glimepiride plasma concentrations, and inducers, such as Rifampicin, which may cause a decrease in concentrations.

Administration and Timing Constraints

Glimepiride is subject to an absorption interaction with the bile acid sequestrant Colesevelam, which officially reduces its total exposure (AUC). To mitigate this effect, the drug must be administered at least 4 hours prior to Colesevelam.

Pharmacodynamic Effects and Restrictions

Official labeling indicates that co-administration with numerous agents results in significant pharmacodynamic interactions. Agents like ACE Inhibitors and Salicylates are documented to potentiate the blood-glucose-lowering effect. Conversely, substances such as Thiazide Diuretics and Glucocorticoids are cited as weakening this effect. The combination with oral Miconazole is formally listed as a contraindicated combination due to the high risk of severe hypoglycemia. Furthermore, alcohol consumption, particularly when combined with irregular or skipped meals, is cited as a factor that may potentiate or weaken the drug's hypoglycemic action.

Mechanism of Action

The mechanism of Diabirel (Glimepiride) involves two key domains: the acute stimulation of hormone release and the enhancement of tissue response to that hormone, which together influence pathways governing glucose transport and production.


Targeted Stimulation of Pancreatic Insulin Secretion

This domain centers on the beta-cell ATP-sensitive potassium channel (K ATP channel), the drug’s primary molecular target. Glimepiride binds to the channel's regulatory SUR1 subunit, forcing it to close, which triggers a rapid cellular cascade involving membrane depolarization and Ca^2+ influx. This process initiates the exocytosis of stored endogenous insulin, leading to an acute increase in the hormone's concentration in the bloodstream.


Influence on Systemic Glucose Transport and Metabolism

This mechanism extends beyond the pancreas, influencing extrapancreatic tissues such as muscle and fat, where it enhances their sensitivity to the newly released insulin. Simultaneously, the elevated insulin acts on the liver to suppress its production and release of glucose (hepatic output). The combination of these actions—forced secretion, enhanced tissue uptake, and reduced liver output—shapes the resulting physiological effect on systemic glucose concentration.

Dosage and Administration Information

Official Instructions for Use

Diabirel is administered orally as a tablet. The dosage regimen must be highly individualized for each patient and adjusted according to the clinical response, as determined by a healthcare provider.

Use Context Recommended Starting Dose Maximum Daily Dose
Central Diabetes Insipidus (Adults & Children) 0.05 mg twice daily 1.2 mg, divided into two or three doses
Primary Nocturnal Enuresis (Patients ge 6 years) 0.2 mg at bedtime 0.6 mg at bedtime

Procedural and Age-Specific Administration Rules:

  • Dosage Adjustment (Titration): The starting dose is an initial recommendation and must be individually adjusted to the optimum therapeutic dose. The dosage may be increased or decreased within the prescribed range as needed to obtain adequate response.
  • Fluid Restriction: When the medicine is used for Primary Nocturnal Enuresis, fluid intake must be strictly limited. This restriction begins 1 hour before the bedtime dose and lasts until the following morning, or at least 8 hours after administration.
  • Diagnostic Use: For evaluation of renal concentration capacity in pediatric patients ge 3 years, a single, one-time dose of 0.6 mg is administered orally at bedtime after the patient has emptied their bladder.
  • Missed Dose: If a dose is missed, the official guidance states to skip the missed dose and resume the regular dosing schedule. A double dose must not be taken to compensate for a forgotten dose.

These official instructions define the required route, dosing limits, frequency, and critical administration conditions for the standardized use of the medication as established by regulatory health authorities.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Diabirel

Evidence for use in Glycemic Control in Type 2 Diabetes

Research has primarily focused on the use of Diabirel in adults with Type 2 Diabetes Mellitus (T2DM). The evidence base includes numerous Randomized Controlled Trials (RCTs) and systematic reviews. Research examined measurements of primary glycemic biomarkers, specifically Glycated Hemoglobin ( HbA1c), and more immediate markers like Fasting Plasma Glucose (FPG) and Postprandial Glucose (PPG) levels.

Studies described the patterns of change measured in these biomarkers across observed populations during the study periods. Furthermore, trials examined outcomes related to first- and second-phase insulin secretion in the observed populations. This research contributes to the understanding of symptom patterns related to outcomes of systemic or functional imbalance in T2DM. However, long-term outcomes are not well characterized by the initial studies used for regulatory approval.


Research on Cardiovascular Outcomes and Safety

Research has also been conducted using long-term comparative effectiveness studies to assess the medication's profile regarding major non-glycemic outcomes. These studies used Diabirel as a comparison agent against some newer diabetes medications in patients with T2DM. The primary outcome was a defined group of events called Major Adverse Cardiovascular Events (MACE), which was defined to include outcomes such as cardiovascular death, non-fatal myocardial infarction (MI), and non-fatal stroke.

One type of study examined comparisons related to non-inferiority on the primary MACE endpoint when compared to certain newer non-sulfonylurea agents. The research also describes that the analysis of data from one specific trial showed patterns related to a higher frequency of recurrent cardiovascular events in the group studied with Diabirel compared to the GLP-1 receptor agonist group.


Key Limitations and Areas of Research Uncertainty

The current research landscape highlights several areas where certainty remains low or where data are still emerging. The official regulatory record notes that the research conducted does not provide conclusive evidence regarding the prevention of macrovascular complications (like heart attack and stroke) associated with diabetes. Few data are available for patients who are very elderly (e.g., over 75 years of age) or for those with significant renal impairment. The existing studies contribute to the broader evidence landscape, and research findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Diabirel (FAQ)


Q: Are there any foods or drinks I should avoid while using Diabirel?

Official documentation cites that alcohol consumption, particularly when combined with irregular or skipped meals, may potentially change the drug's blood sugar-lowering effect. A known interaction exists with the bile acid sequestrant Colesevelam, where the drug’s absorption is reduced. Official guidance addresses this by stating Diabirel should be administered separately from this medication.


Q: What should I know about alcohol consumption while taking Diabirel?

Official information indicates that ingesting alcohol may increase the risk of severe low blood sugar (hypoglycemia). Alcohol consumption, especially when meals are irregular or skipped, is cited as a factor that may either enhance or lessen the blood sugar-lowering action of the medication. This potential interaction is noted in official documentation.


Q: Is it possible for Diabirel to stop working over time?

Regulatory documents state that some patients may experience a loss of adequate blood sugar control over time while using this type of medication. This is a possibility noted in clinical trial outcomes, and it is a known phenomenon that may occur with any blood sugar-lowering agent.


Q: Is Diabirel used in combination with diet and exercise?

Yes, official documentation states that Diabirel is only indicated for use as an adjunct to diet and exercise to improve blood sugar control. Regulatory labeling indicates the medication is utilized as an adjunct to these efforts.


Q: Does Diabirel treat all types of [condition treated]?

Official regulatory documents indicate that Diabirel is specifically intended for use only by adults with Type 2 Diabetes Mellitus (T2DM). Its use is formally contraindicated (must not be used) in patients with Type 1 Diabetes Mellitus or Diabetic Ketoacidosis (DKA).


Q: How quickly should I expect to see the effects of Diabirel?

Pharmacological studies cited in official sources indicate that the drug begins to show a glucose-lowering effect within approximately 2 to 3 hours after administration. The maximum effect generally occurs within this short time frame. The drug’s pharmacological profile is associated with a duration of action of approximately 24 hours.


Q: Why is Diabirel sometimes prescribed with other medications?

Regulatory documents note that the medication is approved for use in combination therapy with certain other blood sugar-lowering agents, such as metformin or insulin. This is generally done if the desired level of blood sugar control is not achieved with Diabirel used alone.


Q: Is it normal to feel [general symptom like tiredness/nausea] when starting Diabirel?

Nausea is listed as an uncommon adverse reaction in clinical trials. Official documentation notes that certain effects, including hypoglycemia (low blood sugar) and transient visual impairment, may be observed more frequently at the start of treatment or following a dose adjustment.


Q: Does using Diabirel cause weight gain or weight loss?

Weight gain has been reported as a known side effect of this drug class. Official documents have cited weight gain as a reported adverse effect.


Q: Is there a generic version of Diabirel available?

Yes, the active ingredient in Diabirel, Glimepiride, is a well-known compound that is officially available as a generic medication.


Q: How long does Diabirel stay in the body after the last use?

Official pharmacokinetic data shows that the elimination half-life of the active ingredient is approximately 5 to 8 hours. The half-life may slightly increase to up to 9 hours following multiple doses.


Q: Can Diabirel cause changes in mood or anxiety?

Official product information notes that symptoms of severe low blood sugar (hypoglycemia), the most common side effect, can include changes in behavior. These changes can involve feelings of irritability, confusion, or anxiety. These mood changes are recognized as potential symptoms of low blood sugar.


Q: Is Diabirel used by children or teenagers?

Official documentation states that the use of Diabirel in pediatric patients (children and teenagers) is not recommended. Safety and effectiveness have not been established in this age group.


Q: What are the most commonly reported less serious side effects of Diabirel?

Common adverse reactions reported in clinical trials include headache, nausea, and dizziness. Other effects classified as uncommon include gastrointestinal disturbances (such as vomiting or diarrhea) and transient visual impairment.


Q: Are there special warnings for older people who use Diabirel?

Official warnings note that older adults are at an increased risk for hypoglycemia (low blood sugar). For this reason, careful dose selection and titration are generally required for this population.


Q: What is the maximum duration of use described for Diabirel?

Regulatory documents describe that clinical studies have included patients treated with Diabirel for extended periods, such as in long-term extension trials spanning 2.5 years. The inclusion of long-term trials in the evidence base supports the common use of the medication over extended periods.


Q: Does Diabirel come in different strengths?

Yes, official regulatory documents confirm that Diabirel (Glimepiride) is available in multiple tablet strengths. These officially include 1 mg, 2 mg, and 4 mg tablets.


Q: Is Diabirel linked to any severe allergic reactions?

Yes, regulatory documents describe that rare but serious reactions are documented. These can include severe hypersensitivity reactions like allergic vasculitis (inflammation of blood vessels) and potentially life-threatening conditions like anaphylaxis.


Q: Do I need to get regular blood tests while on Diabirel?

While the regulatory label does not mandate a specific test frequency, it indicates the drug is used to improve control of glycemic biomarkers like HbA1c and Fasting Plasma Glucose. These are lab markers frequently measured to assess the response to the treatment and to guide dose adjustments.


Q: Can Diabirel be crushed or split?

Official documentation for Diabirel (Glimepiride) tablets indicates that the tablets are scored, meaning they have a break line. This scoring is generally used to facilitate the division of the tablet.


Q: What is the typical age range of people using Diabirel?

Official documents indicate the drug is primarily used in adults with Type 2 Diabetes Mellitus. It is not recommended for use in children or teenagers, and use in the elderly requires careful dose selection due to an increased risk of low blood sugar.

How should Diabirel be stored and disposed of?

How to Store and Dispose of Diabirel?

The official regulatory profile for Diabirel (glimepiride) mandates strict storage and disposal requirements to ensure product stability and safety.


Required Storage Conditions

Diabirel must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). It is essential to protect the tablets from moisture by keeping the medication in its original container and ensuring the container is kept tightly closed. As a mandatory safety requirement, the medicine must be stored out of the sight and reach of children at all times.


Official Disposal Rules

Unused or expired Diabirel must be disposed of properly. Do not flush the tablets down the toilet or pour them into a drain to avoid environmental contamination. The preferred method is to utilize a drug take-back program. If a program is unavailable, follow household disposal procedures by mixing the medication with an undesirable substance, sealing it in a plastic bag, and discarding it with household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Diabirel found in:

A-Z Index: